Signal transducer and activator of transcription 6 (STAT6) is a member of the STAT family involved in the regulation of immune response and inflammation. The development of SH2 domain inhibitors targeting STAT6 may help prevent and treat allergic diseases, asthma, atopic dermatitis or other Th2-driven immune conditions. Researchers from Recludix Pharma Inc. have presented the preclinical profiles of REX-8756 and REX-4671, two STAT6 inhibitors being developed in partnership with Sanofi SA.
Researchers from Tikkunlev Therapeutics Inc. and the University of Utah have presented preclinical data on TLT-101, a gene therapy consisting of an adeno-associated virus serotype 9 (AAV9) vector encoding cardiac bridging integrator 1 (cBIN1) designed for the treatment of heart failure.
Urachal carcinoma is a rare cancer which lacks a standard drug therapy, and for which knowledge regarding its immunohistochemical features remains unclear. The aim of a recently reported investigation was finding potential markers and targets for urachal carcinoma based on antibody-drug conjugate targets, as well as its association with prognosis.
The research on glioblastoma requires the development of new preclinical murine models. The GL261 cell line forms glioma-like tumors in a reliable manner when transplanted intracranially, but these tumors do not completely mimic human glioblastoma. This model responds well to immune checkpoint inhibitors (ICIs), but ICIs have shown limited efficacy in some clinical trials.
The scientific establishment has launched a fight back against the Trump administration and the slew of executive orders that threaten to dismantle research funding, with a warning that the next month could be critical for the future of U.S. science.
Glucocorticoid-induced tumor necrosis factor receptor (GITR) and its ligand, GITRL, are involved in immune response regulation. GITR is mainly expressed in activated T cells while GITRL is primarily found in antigen-presenting cells.
In autoimmune diseases such as inflammatory bowel disease (IBD), the function of regulatory CD8 T cells (CD8 Treg) is compromised, in part due to the expression of inhibitory KIR receptors (KIR2DL1/2/3) and insufficient inducible T-cell co-stimulator (ICOS) signaling. Mozart Therapeutics Inc. has discovered MTX-201, a new bispecific antibody targeting inhibitory KIR and ICOS that are co-expressed by CD8 Tregs.
Researchers from Walter and Eliza Hall Institute of Medical Research, The University of Melbourne and affiliated organizations presented the development of a new reporter mouse model designed to study the role of MDM2 and its transcriptional regulation in p53-mediated tumor suppression.
Prostate cancer is still one of the main causes of cancer death among men; while prostate-specific antigen (PSA) testing is done for screening, there are recommendations against its use due to its nonspecific and suboptimal results. There is thus an urgent need for new biomarkers that are more accurate in the detection of prostate cancer.
Previous research has shown that aberrant sphingolipid metabolism, which is evidenced by elevated levels of circulating ceramide, is associated with poor prognosis in patients with prostate cancer (PC). Work at the University of Adelaide has led to the establishment of a new syngeneic mouse model to study the role of sphingolipid metabolism in PC.